Fulgent Genetics (FLGT) Current Deferred Revenue (2018 - 2026)

Fulgent Genetics has disclosed Current Deferred Revenue across 9 years of filings, most recently posting $3.4 million for Q2 2026.

• In Q2 2026, Current Deferred Revenue rose 27.35% year-over-year to $3.4 million; the TTM figure through Jun 2026 stood at $3.4 million (up 27.35% YoY), while the FY2025 annual figure was $3.6 million, up 62.71% from the prior year.
• Current Deferred Revenue came in at $3.4 million for Q2 2026 at Fulgent Genetics, up from $3.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $14.1 million in Q1 2022 to a low of $2.2 million in Q4 2024.
• Average Current Deferred Revenue over 5 years is $3.9 million, with a median of $2.8 million recorded in 2024.
• Year-over-year, Current Deferred Revenue tumbled 80.62% in 2023 and soared 62.71% in 2025.
• Over 5 years, Current Deferred Revenue stood at $3.2 million in 2022, then dropped by 10.16% to $2.9 million in 2023, then fell by 22.27% to $2.2 million in 2024, then soared by 62.71% to $3.6 million in 2025, then declined by 6.35% to $3.4 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $3.4 million in Q2 2026, $3.0 million in Q1 2026, and $3.6 million in Q4 2025.